ClinicalTrials.gg
RecruitingNCT06689163Updated Sep 3, 2025

A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone

A Phase 1/2 interventional study of HRS-1167 tablets and Abiraterone Acetate tablets(II) in Prostate Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Recruiting at 2 sites in China. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-03.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Nov 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
66
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies in Prostatic Neoplasms by Jiangsu HengRui Medicine Co., Ltd. — 14 open to participants now, 17 under way, 4 of them phase 3. Prostatic Neoplasms · Jiangsu HengRui Medicine Co., Ltd..

Planned enrollment
17th of 31
66 · median 69
Started
2024
with 2 others
Phase 1/2
7 of 31
5 open now
Primary completion
2025-11
later than 4 of 16 live
Registered
21st of 31
by date

Among the 31 studies in Prostatic Neoplasms by Jiangsu HengRui Medicine Co., Ltd., this one is the 17th largest by planned enrollment, is one of 3 that started in 2024, is one of 7 in phase 1/2, reaches primary completion later than 4 of the 16 other live ones, and was the 21st registered.

Prostatic Neoplasms

7,052 studies on the registry are indexed under Prostatic Neoplasms; 1,583 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

14 of the 31 studies in Prostatic Neoplasms by Jiangsu HengRui Medicine Co., Ltd. are open now, in 2 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 1,231 Prostatic Neoplasms studies recruiting now, 930 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Prostatic Neoplasms by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

The purpose of this study was to observe and evaluate the tolerability, safety, and pharmacokinetics of HRS-1167 combined with abiraterone acetate tablets (II) and prednisone in patients with metastatic prostate cancer, determine the RP2D, and evaluate the effectiveness.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary participation in this study, signed , compliance is good, and are willing and able to comply with planned visits.
  2. The age is above 18 years old, male.
  3. Adenocarcinoma of the prostate confirmed with histologically or cytologically.
  4. lesions were confirmed by CT/MRI or radionuclide bone scan (99mTc).
  5. score is 0 or 1.
  6. An expected survival of ≥ 12 weeks.
  7. Male subjects whose partner is women of (WOCBP) are required to use highly effective from the date of signing the informed consent until 120 days after the last dose of the drug.

Exclusion criteria

Exclusion Criteria:

  1. Received systemic antitumor therapy 4 weeks before starting study treatment; Participants who are participating in another clinical study or whose first dose is less than 4 weeks from the end of the previous clinical study (last dose), or five half-lives of the drug, whichever is shorter; Patients who had previously received anti-tumor proprietary Chinese medicine could be enrolled if the interval between the end of treatment and the first study was not less than 2 weeks.
  2. Subjects had prior or co-existing , except for cured basal cell carcinoma of the skin, papillary carcinoma of the thyroid, and other malignancies that had been adequately treated and cured for ≥ 3 years prior to the first dose with evidence of no recurrence or .
  3. Subjects had cancerous meningitis or untreated central nervous system metastases.
  4. Imaging showed that the tumor invaded large blood vessels or had unclear boundary with blood vessels. Or patients whose tumors are judged by the investigators to be at high risk of invading vital blood vessels during treatment and causing fatal bleeding.
  5. Patients with clinical symptoms of cancerous ascites and pleural effusion requiring puncture and drainage; Or received ascites, pleural effusion drainage within 14 days before the first dose.
  6. Severe bone injury due to tumor bone metastasis, including poorly controlled severe bone pain, pathological bone fractures and spinal cord compression that occurred within the last 6 months or are likely to occur in the near future.
  7. Pneumonia with past or current interstitial pneumonia/interstitial lung disease requiring treatment with the system; Patients with active pneumonia or severe impairment of lung function confirmed by pulmonary function examination.
  8. Systemic therapy with corticosteroids or other within 2 weeks prior to the first dose.
  9. Those with active pulmonary tuberculosis; Patients who had been adequately treated and had stopped anti-tuberculosis therapy for ≥3 months before the first dose could be enrolled.
  10. Have high blood pressure that is not well controlled by antihypertensive medication; A history of hypertensive crisis or hypertensive encephalopathy.
  11. Have clinical symptoms or diseases of the heart that are not well controlled.
  12. Arterial/venous thrombosis events occurred within 6 months prior to the first dose.
  13. Inability to swallow pills normally, or gastrointestinal dysfunction, may affect drug absorption.
  14. Subjects who had a severe infection within 1 month prior to the first dose.
  15. A known history of positive; Known to have active hepatitis.
  16. The toxicity caused by previous antitumor therapy has not recovered to ≤ grade 1.
  17. was administered within 4 weeks prior to the first dose or possibly using during the study.
  18. In the judgment of the investigator, there are other factors that may affect the results of the study or cause the study to be terminated.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    HRS-1167 combined with abiraterone acetate tablets (II) and prednisone

    Drug: HRS-1167 tablets · Drug: Abiraterone Acetate tablets(II) · Drug: Prednisone Acetate tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Dose limiting toxicity (DLT)

    Time frame: 28 days

  2. Recommended phase II dose (RP2D)

    Time frame: 28 days

  3. The dose suspension rate caused by drug-related adverse events

    Time frame: 2 years

  4. The dose downregulation rate caused by drug-related adverse events

    Time frame: 2 years

  5. The dose termination rate caused by drug-related adverse events

    Time frame: 2 years

Secondary outcomes

  1. PSA response rate

    Time frame: 1 year

  2. Time to PSA progression as assessed by the investigator

    Time frame: 1 year

  3. Objective response rate (ORR)

    Time frame: 1 year

  4. Disease control rate (DCR)

    Time frame: 1 year

  5. Duration of response (DoR)

    Time frame: 1 year

  6. Time to remission (TTR)

    Time frame: 1 year

  7. Radiographic progression-free survival (rPFS)

    Time frame: 1 year

  8. Overall survival (OS)

    Time frame: 3 years

  9. Steady-state peak concentration (Cmax,ss) of HRS-1167

    Time frame: 16 weeks

  10. Adverse events

    Time frame: 2 years

  11. 12-lead electrocardiogram

    Time frame: 2 years

  12. ECOG score

    Time frame: 2 years

  13. Steady-state peak time (Tmax,ss) of HRS-1167

    Time frame: 16 weeks

  14. Steady-state valley concentration (Cmin,ss)

    Time frame: 16 weeks

  15. Steady-state area under the concentration-time curve (AUCss)

    Time frame: 16 weeks

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Nov 2025, 11 months after the start.

Of 96 industry-sponsored phase 1/2 interventional studies under Prostatic Neoplasms, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35. This study's planned 11 months is below that.

Counting every sponsor, half of 210 studies reached it within 61 months; a quarter within 30 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2024
First posted
Nov 14, 2024
StartActual
Dec 11, 2024
Primary completionEst.
Nov 30, 2025
CompletionEst.
Dec 31, 2026
Last update
Sep 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06689163
Responsible party
Sponsor
First posted
Nov 14, 2024
Start date
Dec 11, 2024
Primary completion
Nov 30, 2025 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Sep 3, 2025

Study contacts

Ke Liu, M.M
Contact
ke.liu.kl53@hengrui.com
0518-81220121

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PARP1 Inhibitor HRS-1167

Start the discussion